- Home
- BCTX vs CANF Comparison
BCTX vs CANF Comparison
Compare BCTX & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- CANF
- Stock Information
- Founded
- BCTX 2014
- CANF 1994
- Country
- BCTX Canada
- CANF Israel
- Employees
- BCTX N/A
- CANF N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- BCTX Health Care
- CANF Health Care
- Exchange
- BCTX Nasdaq
- CANF Nasdaq
- Market Cap
- BCTX 13.7M
- CANF 13.5M
- IPO Year
- BCTX N/A
- CANF N/A
- Fundamental
- Price
- BCTX $0.69
- CANF $0.70
- Analyst Decision
- BCTX Strong Buy
- CANF Strong Buy
- Analyst Count
- BCTX 1
- CANF 2
- Target Price
- BCTX $32.00
- CANF $14.00
- AVG Volume (30 Days)
- BCTX 2.1M
- CANF 330.4K
- Earning Date
- BCTX 06-16-2025
- CANF 08-29-2025
- Dividend Yield
- BCTX N/A
- CANF N/A
- EPS Growth
- BCTX N/A
- CANF N/A
- EPS
- BCTX N/A
- CANF N/A
- Revenue
- BCTX N/A
- CANF $674,000.00
- Revenue This Year
- BCTX N/A
- CANF $461.72
- Revenue Next Year
- BCTX N/A
- CANF N/A
- P/E Ratio
- BCTX N/A
- CANF N/A
- Revenue Growth
- BCTX N/A
- CANF N/A
- 52 Week Low
- BCTX $0.61
- CANF $0.63
- 52 Week High
- BCTX $29.40
- CANF $3.12
- Technical
- Relative Strength Index (RSI)
- BCTX 21.33
- CANF 22.87
- Support Level
- BCTX $0.61
- CANF $0.68
- Resistance Level
- BCTX $0.78
- CANF $1.05
- Average True Range (ATR)
- BCTX 0.05
- CANF 0.05
- MACD
- BCTX 0.07
- CANF -0.01
- Stochastic Oscillator
- BCTX 34.43
- CANF 15.83
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).